VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

IMM-101
Vaccine Information
  • Vaccine Name: IMM-101
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0007622
  • Type: Inactivated or "killed" vaccine
  • Status: Research
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: IMM-101, a suspension of heat-killed whole cell Mycobacterium obuense. IMM-101 is safe and well tolerated and there is a rationale for studying IMM-101 at a nominal 1.0-mg dose to complement conventional cytotoxic therapy for patients with advanced cancer (Stebbing et al., 2012).
Host Response

Human Response

  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Induced specific maturation of monocyte-derived dendritic cells (DCs), which when placed in culture with naive CD4+ T cells is associated with inhibition of IL-4 and induction of CD25+FoxP3+ cells (Stebbing et al., 2012).
References
Stebbing et al., 2012: Stebbing J, Dalgleish A, Gifford-Moore A, Martin A, Gleeson C, Wilson G, Brunet LR, Grange J, Mudan S. An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012; 23(5); 1314-1319. [PubMed: 21930686].